SAB BIO to Participate in Upcoming Investor Conferences [Yahoo! Finance]
SAB Biotherapeutics, Inc. (SABS)
Company Research
Source: Yahoo! Finance
In This Article SABS SABSW SAB Biotherapeutics, Inc. MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS ), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing SAB-142, a human anti-thymocyte immunoglobulin (hIgG) that potentially delays the onset or progression of type 1 diabetes (T1D), today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim SMID Cap Biotech Conference Date: February 6, 2025 Fireside Chat: 2:00 – 2:25pm ET Webcast Link: https://wsw.com/webcast/guggen2/sabs/1999239 Event: Oppenheimer 35 th Annual Healthcare Life Sciences Conference Date: February
Read more
Impact Snapshot
Event Time:
SABS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SABS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SABS alerts
High impacting SAB Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SABS
News
- SAB BIO to Participate in Upcoming Investor ConferencesGlobeNewswire
- SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.MarketBeat
- SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142GlobeNewswire
- SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D TherapyGlobeNewswire
SABS
Earnings
- 11/6/24 - Miss
SABS
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/5/25 - Form 8-K
- 1/28/25 - Form 8-K
- SABS's page on the SEC website